Interestingly, both neuroendocrine cancers and relapsed or refractory (R/R) AML are predominantly driven by TP53 mutations, which are closely associated with treatment resistance [1, 10, 11, 13]. Here, TP53 is linked to neuroendocrine carcinoma.